Detalles de la búsqueda
1.
Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
Am Heart J
; 216: 30-41, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31386936
2.
Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data.
Adv Ther
; 41(6): 2519-2530, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38698169
3.
Assessing the impact of single or short-term administration on a therapy's cost-effectiveness: a hypothetical disease-agnostic model.
J Med Econ
; 26(1): 594-602, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37026587
4.
Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
J Manag Care Spec Pharm
; 29(5): 472-479, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36864544
5.
Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec.
Mol Ther Methods Clin Dev
; 30: 474-483, 2023 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674905
6.
Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States.
J Mark Access Health Policy
; 11(1): 2216518, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37261034
7.
Characterizing the Occurrence of Key Clinical Milestones in Duchenne Muscular Dystrophy in the United States Using Real-World Data.
J Neuromuscul Dis
; 9(6): 689-699, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36245384
8.
Erratum to 'Lipid Treatment and Goal Attainment Characteristics among Persons with Atherosclerotic Cardiovascular Disease in the United States' [American Journal of Preventive Cardiology 1C (2020) 100010].
Am J Prev Cardiol
; 5: 100160, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34374692
9.
Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.
J Manag Care Spec Pharm
; 27(10): 1426-1437, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34595954
10.
Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States.
Am J Prev Cardiol
; 1: 100010, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34327452
11.
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Am J Cardiol
; 123(8): 1202-1207, 2019 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30736965
12.
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
JAMA Cardiol
; 2(9): 959-966, 2017 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28768335
Resultados
1 -
12
de 12
1
Próxima >
>>